Suppr超能文献

头颈部副神经节瘤患者的管理和随访策略。

Management and follow-up strategies for patients with head and neck paraganglioma.

机构信息

Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.

Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda 20892, MD, United States.

出版信息

Eur J Endocrinol. 2024 Sep 30;191(4):389-398. doi: 10.1093/ejendo/lvae113.

Abstract

OBJECTIVE

Head-neck paragangliomas (HNPGLs) are rare tumors with approximately half arising due to germline pathogenic variants (PVs) in succinate dehydrogenase genes (SDHx). Patients with HNPGL have heterogeneous propensity to recur and metastasize. Thus, we aim to assess prevalence and predictors of recurrent (RD) and/or metastatic disease in patients with and without SDHx-related HNPGLs.

DESIGN AND METHODS

This cross-sectional study used retrospective data of 214 patients enrolled in six referral centers. Data included sex, age, primary tumor treatment, location, and size, biochemical phenotype, germline PVs, presence of RD (locoregional or new tumor), and/or metastasis.

RESULTS

Patients with and without SDHx-related HNPGLs showed 74% and 40% prevalence of RD, respectively. Patients without SDHx-related HNPGLs presented with recurrent tumors only in head-neck regions. The only independent predictor for RD in the entire cohort was presence of SDHx PVs. Metastatic prevalence reached 9%-13%. For patients with SDHx-related HNPGLs, large tumor size (>2.3 cm, OR:50.0, CI:2.6-977.6), young age at initial diagnosis (<42years, OR:27.3, CI:1.8-407.2), and presence of SDHB PV (OR:15.6; CI:1.5-164.8) were independent predictors of metastasis. For patients without SDHx-related HNPGLs, only carotid-body location was an independent predictor of metastasis (OR:18.9, CI:2.0-182.5).

CONCLUSIONS

Patients without SDHx-related HNPGLs require long-term follow-up due to high prevalence of RD with imaging largely restricted to head-neck regions. As carotid-body HNPGLs have the highest metastatic risk among sporadic tumors, radical treatment with frequent follow-up is suggested until population-based data are available. Importantly, patients with SDHx-related HNPGLs might benefit from early radical treatment when tumors are still small to reduce metastatic risk.

摘要

目的

头颈部副神经节瘤(HNPGL)是一种罕见的肿瘤,大约有一半是由于琥珀酸脱氢酶基因(SDHx)的种系致病性变异(PV)引起的。HNPGL 患者具有异质性的复发和转移倾向。因此,我们旨在评估有和没有 SDHx 相关 HNPGL 的患者中复发(RD)和/或转移性疾病的患病率和预测因素。

设计和方法

这项横断面研究使用了六个转诊中心 214 名患者的回顾性数据。数据包括性别、年龄、原发肿瘤治疗、位置和大小、生化表型、种系 PV、RD(局部或新肿瘤)和/或转移的存在。

结果

有和没有 SDHx 相关 HNPGL 的患者 RD 的患病率分别为 74%和 40%。没有 SDHx 相关 HNPGL 的患者仅在头颈部区域出现复发性肿瘤。整个队列中 RD 的唯一独立预测因素是存在 SDHx PV。转移的患病率达到 9%-13%。对于有 SDHx 相关 HNPGL 的患者,肿瘤较大(>2.3cm,OR:50.0,CI:2.6-977.6)、初始诊断年龄较小(<42 岁,OR:27.3,CI:1.8-407.2)和存在 SDHB PV(OR:15.6;CI:1.5-164.8)是转移的独立预测因素。对于没有 SDHx 相关 HNPGL 的患者,只有颈动脉体位置是转移的独立预测因素(OR:18.9,CI:2.0-182.5)。

结论

没有 SDHx 相关 HNPGL 的患者需要长期随访,因为影像学检查主要局限于头颈部区域,复发率较高。由于散发性肿瘤中颈动脉体 HNPGL 的转移风险最高,建议进行根治性治疗,并进行频繁随访,直到获得人群数据。重要的是,当肿瘤还小时,SDHx 相关 HNPGL 的患者可能受益于早期根治性治疗,以降低转移风险。

相似文献

1
Management and follow-up strategies for patients with head and neck paraganglioma.
Eur J Endocrinol. 2024 Sep 30;191(4):389-398. doi: 10.1093/ejendo/lvae113.
2
[Ga]DOTATOC PET-derived radiomics to predict genetic background of head and neck paragangliomas: a pilot investigation.
Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2684-2694. doi: 10.1007/s00259-024-06735-5. Epub 2024 Apr 30.
3
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.
Endocr Relat Cancer. 2022 Mar 21;29(4):213-224. doi: 10.1530/ERC-21-0359.
4
Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update.
Horm Metab Res. 2012 May;44(5):349-53. doi: 10.1055/s-0032-1311610. Epub 2012 May 7.
5
Characterization of Malignant Head and Neck Paragangliomas at a Single Institution Across Multiple Decades.
JAMA Otolaryngol Head Neck Surg. 2019 Jul 1;145(7):641-646. doi: 10.1001/jamaoto.2019.1110.
6
18F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas.
Eur J Clin Invest. 2014;44(3):325-332. doi: 10.1111/eci.12239.
7
Clinical management and outcome of head and neck paragangliomas (HNPGLs): A single centre retrospective study.
Clin Endocrinol (Oxf). 2024 Sep;101(3):243-248. doi: 10.1111/cen.15070. Epub 2024 May 2.
9
FDG PET-CT imaging in head and neck paragangliomas: A centre experience.
Clin Endocrinol (Oxf). 2021 Aug;95(2):315-322. doi: 10.1111/cen.14446. Epub 2021 May 30.
10

引用本文的文献

1
Pheochromocytomas and Paragangliomas-Current Management.
Cancers (Basel). 2025 Mar 19;17(6):1029. doi: 10.3390/cancers17061029.

本文引用的文献

2
Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.
Lancet Digit Health. 2023 Sep;5(9):e551-e559. doi: 10.1016/S2589-7500(23)00094-8. Epub 2023 Jul 18.
3
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants.
Lancet Diabetes Endocrinol. 2023 May;11(5):345-361. doi: 10.1016/S2213-8587(23)00038-4. Epub 2023 Mar 31.
5
Metabolomics in paraganglioma: applications and perspectives from genetics to therapy.
Endocr Relat Cancer. 2023 May 11;30(6). doi: 10.1530/ERC-22-0376. Print 2023 Jun 1.
6
Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
J Clin Endocrinol Metab. 2023 Jan 17;108(2):397-404. doi: 10.1210/clinem/dgac563.
7
Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.
Eur J Cancer. 2022 Jul;169:32-41. doi: 10.1016/j.ejca.2022.03.032. Epub 2022 Apr 29.
8
Somatic Mutation Profiling in Head and Neck Paragangliomas.
J Clin Endocrinol Metab. 2022 Jun 16;107(7):1833-1842. doi: 10.1210/clinem/dgac250.
9
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Endocr Pathol. 2022 Mar;33(1):90-114. doi: 10.1007/s12022-022-09704-6. Epub 2022 Mar 13.
10
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.
Endocr Relat Cancer. 2022 Mar 21;29(4):213-224. doi: 10.1530/ERC-21-0359.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验